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Dear Editor,
Thrombotic thrombocytopenic purpura (TTP) is a rare
disease, characterised by thrombocytopenia and micro-
angiopathic haemolytic anaemia. Under normal circum-
stances, unusually large multimers (UL) of von Willebrand
factor (VWF) are released by activated endothelial cells and
subsequently rapidly proteolysed by ADAMTS-13 into
smaller, less active forms. In TTP, the released ULVWF
persist in the circulation due to a lack of ADAMTS-13,
prompting the formation of micro-thrombi and micro-
vascular obstruction [1]. Although the primary defect
underlying TTP is presumed to be a deficiency of
ADAMTS-13, the deficiency on its own seems not
sufficient for the disease to become clinically apparent [2].
In an attempt to gain more insight into the mechanism of
TTP, we recently evaluated ADAMTS-13 activity and
plasma VWF multimer distribution patterns, expressed as
VWF:Collagen binding/VWF:Antigen (VWF:CB/VWF:
Ag) ratio, in relation to platelet treatment–response patterns
during the first 14 days of plasma exchange (PE) in 26
disease episodes in 21 patients with idiopathic TTP
consecutively admitted at our institution from 1994 to
2006. The observations are explained in a model in which
acute thrombotic episodes in TTP are triggered by a
mechanism of platelet activation besides endothelial cell
activation.
All patients followed a uniform treatment scheme
including daily plasma exchange (PE) with fresh frozen
plasma replacement (50 ml/kg/day) in combination with
prednisone 1.5 mg kg/day/p.o. for 2–3 weeks followed by a
tapering scheme of 10 mg reduction per 2 days to stop.
After normalisation of the platelet count (>140×10
9/l for
three consecutive days), PE was tapered to stop within
2 weeks (first week3 and second week2 PE's). Patients'
informed consent was obtained at a recent outpatient visit
or by telephone if discharged from follow-up. ADAMTS-
13 activity (detection limit 3%) was measured as described
[3, 4]. Anti-ADAMTS-13 IgG auto-antibodies were
detected with an enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer's instructions
(American Diagnostica Inc., Stamford CT, USA, normal
range 2.1–12.8, mean 7.2, SD 3.6, n=9) and in some cases
with mixing experiments. VWF:Ag and VWF:CB were
measured with an in-house sandwich ELISA [5, 6]. For
analysis of the proteolytic fragments of VWF, blood
samples were reduced, separated by gel electrophoresis
and visualised as described [7, 8]. IgG (MW 150 kD) and
IgE (MW 196 kD), visualised in untreated plasma, were
used as internal molecular weight standards by identifica-
tion of the VWF fragments. The relative amount of the
proteolytic VWF fragments was measured using Image
Quant 5.2 by calculating the area under the peak. The
biological variability between normal donors for the
225-kD VWF subunit, the 176- and 189-kD proteolytic
fragments was 80.0±6.3%, 17.8±6.3% and 1.6±0.9%,
respectively (n=14).
Four different platelet–treatment response patterns were
discerned (types I–IV, Table 1 and Fig. 1). Of special
interest are the response patterns II and III which can be
distinguished by a normal VWF:CB/VWF:Ag ratio and a
normal amount (as determined in three patients) of the 176-
kD proteolytic VWF fragments in type II from that of type
III with a reduced VWF:CB/VWF:Ag ratio and increased
amounts (37.1±20.0%, n=3) of 176-kD VWF cleavage
fragments at diagnosis. The increased amount of the 176-
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1026 Ann Hematol (2009) 88:1025–1028kD VWF cleavage fragments points to increased proteolysis
of VWF by ADAMTS-13 [9]. Type IV is distinguished
from types II and III by persistently decreased ADAMTS-
13 due to the presence of auto-antibodies.
The treatment of type I patients was unsuccessful
without normalisation of the platelet count, ADAMTS-13
activity and VWF:CB/VWF:Ag ratio. In types II, III and IV
patients, platelet counts rose rapidly after initiation of
treatment, eventually resulting in continuing remissions
during the follow-up period of ≥1 year. Two of the five
relapse episodes (all being first relapses occurring after a
relapse-free interval of ≥1 year) showed the same response
pattern as before whereas in the other three relapse
episodes, a different response pattern was observed.
Remarkably, durable remissions in type III responses were
preceded by a short-lasting normalisation of the platelet
count (>140×10
9/l) during which ADAMTS-13 activity
was significantly lower (P<0.05) than in type II responses
at the same stage of treatment. The occurrence of an early
drop in platelet count in type III might have been triggered
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Fig. 1 Mean values of ADAMTS-13 activity (filled square), VWF:
CB/VWF:Ag ratio (empty square) and platelet count (filled triangle)
during the first 2 weeks from the start of PE in four different
treatment–response types in 26 treatment episodes in 21 patients with
idiopathic TTP
Ann Hematol (2009) 88:1025–1028 1027by the tapering (according to protocol) of PE at a moment
when the platelet count was already restored but
ADAMTS-13 activity was still very low. This may
implicate a need for prolonging PE treatment in patients
in whom a type III response pattern is identified.
The significant correlation (Pearson R
2=0.9289, P=
0.0019) between the rise of the (log) platelet count and the
increase of ADAMTS-13 activity which was noticed in type
II during the first 6 days of PE treatment (Fig 1), suggests
decreasing microthrombi formation, thereby supporting the
model in which ADAMTS-13 directly regulates the forma-
tion of micro-thrombi [10]. In contrast, during the first 6 days
of treatment in type III, the rise of the (log) platelet count did
not correlate with the ADAMTS-13 activity but was
significantly correlated with the rise of the VWF:CB/VWF:
Ag ratio (Pearson, R
2=0.7269, P=0.031). The response
pattern suggests that in type III, PE primarily influences the
interaction between VWF and platelets, rather than that it
supplies deficient or non-functional ADAMTS-13.
Regarding the mechanism of the different treatment–
response patterns in types II and III, one can only speculate.
Key roles seem to be reserved for activation of the endothelial
cell (type II) or the platelets (type III). Endothelial cell
activationstimulatesexcretionofULVWF,therebypromoting
shear dependent micro-thrombi formation by VWF–platelet
GPIbα interaction. This process is independent of platelet
activation but is enhanced by reduced proteolytic degradation
of the ULVWF multimers because of deficient ADAMTS-13
activity [1]. By consequence, no excess of VWF proteolytic
fragments is detected, as was the case in the type II responses
that were examined.
Micro-thrombi may also be formed as the result of
interaction of plasma VWF with platelet GPIIb/IIIa
(αIIbβ3), activated by still unknown factors. Insufficient
feedback of microthrombi formation by plasma ADAMTS-
13, which has been shown to affect the size of micro-
thrombi, may cause microvascular thrombosis of TTP [11].
Type III (and possibly also types I and IV) responses are
examples of increased interaction of plasma VWF with
platelets. Platelet-ADAMTS-13 which is released after
platelet activation and which is less susceptible to inhibition
by plasma anti-ADAMTS-13 antibodies [12, 13], might
elicit low-grade degradation of VWF-thrombi as shown by
an increase of 176-kD proteolytic VWF fragments in
plasma in the examined cases.
Whether these or other mechanisms, besides lack of
ADAMTS-13 activity, play a role in triggering clinical
manifestations of TTP remains to be determined.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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